Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lanthier

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nature Reviews. Drug Discovery|January 31, 2015
Regulatory watch: Innovation in biologic new molecular entities: 1986-2014Kathleen L Miller, Michael Lanthier
Health Affairs (Project Hope)|January 8, 2024
Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication ApprovalsKathleen L Miller, Michael Lanthier
Orphanet Journal of Rare Diseases|October 24, 2018
Investigating the landscape of US orphan product approvalsKathleen L Miller, Michael Lanthier
Health Affairs (Project Hope)|March 9, 2016
Trends In Orphan New Molecular Entities, 1983-2014: Half Were First In Class, And Rare Cancers Were The Most Frequent TargetKathleen L Miller, Michael Lanthier
Nature Reviews. Drug Discovery|July 26, 2008
Economic issues with follow-on protein productsMichael Lanthier, Rachel Behrman, Clark Nardinelli
The New England Journal of Medicine|July 4, 2008
Drug-review deadlines and safety problemsClark Nardinelli, Michael Lanthier, Robert Temple
Nature Reviews. Drug Discovery|August 22, 2015
Regulatory watch: What drives differences in review times among CDER divisions?Andreas Schick, Kathleen L Miller, Michael Lanthier, et al.
Health Affairs (Project Hope)|August 7, 2013
An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011Michael Lanthier, Kathleen L Miller, Clark Nardinelli, et al.
Drug Safety|March 26, 2017
Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety WithdrawalsAndreas Schick, Kathleen L Miller, Michael Lanthier, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nature Reviews. Drug Discovery|January 31, 2015
Regulatory watch: Innovation in biologic new molecular entities: 1986-2014Kathleen L Miller, Michael Lanthier
Health Affairs (Project Hope)|January 8, 2024
Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication ApprovalsKathleen L Miller, Michael Lanthier
Orphanet Journal of Rare Diseases|October 24, 2018
Investigating the landscape of US orphan product approvalsKathleen L Miller, Michael Lanthier
Health Affairs (Project Hope)|March 9, 2016
Trends In Orphan New Molecular Entities, 1983-2014: Half Were First In Class, And Rare Cancers Were The Most Frequent TargetKathleen L Miller, Michael Lanthier
Nature Reviews. Drug Discovery|July 26, 2008
Economic issues with follow-on protein productsMichael Lanthier, Rachel Behrman, Clark Nardinelli
The New England Journal of Medicine|July 4, 2008
Drug-review deadlines and safety problemsClark Nardinelli, Michael Lanthier, Robert Temple
Nature Reviews. Drug Discovery|August 22, 2015
Regulatory watch: What drives differences in review times among CDER divisions?Andreas Schick, Kathleen L Miller, Michael Lanthier, et al.
Health Affairs (Project Hope)|August 7, 2013
An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011Michael Lanthier, Kathleen L Miller, Clark Nardinelli, et al.
Drug Safety|March 26, 2017
Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety WithdrawalsAndreas Schick, Kathleen L Miller, Michael Lanthier, et al.
Pageof 1